Skip to main content

Table 1 Experiences with selection and deselection of Nordic trial sites during site selectiona

From: Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations

Site-related qualitySurvey questionResponse
Yes (%)No (%)
Experience in conducting clinical trials /
Interest and commitment
1. Have you experienced that your company selected/recommended an inexperienced trial site in favor of an experienced trial site during site selection due to a higher level of interest and commitment?5248
Interest and commitment2. Have you experienced that your company selected/recommended a trial site unknown to your company in favor of a well-known trial site due to a higher level of interest and commitment?5743
Timely patient recruitment /
Key opinion leader
3. Have you experienced that your company selected/recommended a trial site despite an insufficient recruitment in prior trials, because a key opinion leader was associated with the site?6337
Timely patient recruitment4. Have you experienced that your company deselected/did not recommend a trial site that delivered a timely patient recruitment in prior trials, because your company found it difficult to cooperate with the site in those prior trials?5347
Costs at the site5. Have you experienced that the trial sites selected by the affiliate(s) were not approved by the headquarters because the costs of running the trial at the trial sites were too high?b3763
Costs at the site6. Have you experienced that your company did not recommend trial sites to a sponsor because the costs of running the trial at the trial sites were too high?c2575
  1. a Respondents (n = 83) were asked about their experiences with site selection at the company they worked for. The words selected and deselected applied to biopharmaceutical respondents whereas the words recommended and did not recommend applied to clinical research organization respondents
  2. b This question only applied to biopharmaceutical respondents (n = 43)
  3. c This question only applied to clinical research organization respondents (n = 40)